Clinical Trials Browser

Has results × Neoplasms × Nivolumab × Clear all

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Melanoma, Neoplasms

NCT03388190 2026-02-13

METIMMOX

Phase 2 Completed

80 enrolled 13 charts

Neoplasm Metastasis, Neoplasms

NCT03963518 2025-10-06

SURROGATE-ICI

631 enrolled 6 charts

Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Neoplasms

NCT03937219 2025-09-10

COSMIC-313

Phase 3 Active not recruiting

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT03697564 2025-08-06

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

2 enrolled 10 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT03447470 2025-01-29

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Phase 1 Completed

46 enrolled 29 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasms, Thymus Neoplasms

NCT04350463 2025-01-22

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Phase 2 Completed

92 enrolled 25 charts

Neoplasms, Small Cell Lung Carcinoma

NCT04109066 2025-01-08

CheckMate 7FL

Phase 3 Completed

521 enrolled 17 charts

Breast Neoplasms, Neoplasms

NCT03296137 2024-10-26

Adoptive Cell Therapy Across Cancer Diagnoses

Phase 1/2 Completed

25 enrolled 9 charts

Neoplasms

NCT02664181 2024-09-03

PRECISE

Phase 2 Completed

13 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03190265 2024-08-07

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Phase 2 Completed

61 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasms, Pancreatic Neoplasms

NCT04319224 2024-05-30

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Phase 1/2 Terminated

4 enrolled 10 charts

Neoplasms

NCT02705105 2024-04-25

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

114 enrolled 19 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03123783 2023-12-26

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Phase 1/2 Completed

140 enrolled 16 charts

DermatologicThoracic

Lung Neoplasms, Melanoma, Neoplasms

NCT02439450 2023-09-21

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Phase 1/2 Completed

121 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02904226 2023-07-03

ICONIC

Phase 1/2 Completed

242 enrolled 29 charts

Neoplasms

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

80 enrolled 33 charts

Neoplasms

NCT01714739 2023-02-02

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Completed

337 enrolled 42 charts

Neoplasms

NCT04075604 2022-08-10

CheckMate 7A8

Phase 2 Completed

23 enrolled 20 charts

Breast Neoplasms, Neoplasms

NCT02832167 2022-05-09

CheckMate 627

Phase 2 Completed

239 enrolled 22 charts

Neoplasms

NCT03271047 2022-01-04

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Phase 2 Completed

75 enrolled 17 charts

Neoplasms

NCT03363776 2020-12-19

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

Phase 1/2 Terminated

10 enrolled 11 charts

Neoplasms

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Phase 1/2 Terminated

7 enrolled 6 charts

Neoplasms

NCT03026166 2020-07-17

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Phase 1/2 Terminated

42 enrolled 15 charts

Neoplasms, Small Cell Lung Carcinoma

NCT00441337 2015-02-20

MDX1106-01

Phase 1 Completed

39 enrolled 28 charts

DermatologicGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms